Glass House Brands (GLAS) Depreciation & Amortization (CF) (2020 - 2026)
Glass House Brands' (GLAS) quarterly Depreciation & Amortization (CF) came in at $4.0 million in Q1 2026, up 4.82% year-on-year from $3.8 million in Q1 2025, and up 23.22% on a QoQ basis from $3.3 million in Q4 2025.
Glass House Brands (GLAS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $4.0 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 4.82% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $15.2 million, a 0.13% change from a year earlier, with the FY2025 full-year figure at $15.0 million, changed 0.29% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $4.0 million, up from $3.3 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for GLAS reached as high as $4.0 million in Q1 2026 and fell as low as $2.6 million in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $3.6 million across 5 years, with a median of $3.7 million in 2024.
- Across the five-year window, Depreciation & Amortization (CF) soared 339.13% in 2022 and dropped 15.75% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $3.4 million in 2022, then grew by 3.88% to $3.5 million in 2023, then grew by 9.27% to $3.9 million in 2024, then decreased by 15.75% to $3.3 million in 2025, then rose by 23.22% to $4.0 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $4.0 million in Q1 2026, $3.3 million in Q4 2025, and $4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 22.60 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.02 Mn |
| Mar 31, 2026 | 4.02 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 3.91 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Sep 30, 2024 | 3.73 Mn |
| Sep 30, 2024 | 3.73 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Dec 31, 2023 | 3.55 Mn |